Business Context and Reporting Period
This Form 8-K Current Report was filed by Tivic Health Systems, Inc. (Nasdaq: TIVC) on February 24, 2025, reporting events occurring on February 18, 2025. The filing discloses the appointment of a new senior executive and the terms of his employment agreement.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and corporate governance.
Material Changes
- Executive Appointment: Michael Handley was appointed as Chief Operating Officer (COO) and President of the Tivic Biopharma division effective February 18, 2025.
- Compensation Structure: Mr. Handley's employment agreement includes a base salary of $300,000 per annum and eligibility for an annual incentive bonus up to 35% of base salary.
- Equity Grant: As an inducement to employment, Mr. Handley received a grant of 600,000 restricted stock units (RSUs). This grant was made outside the company's 2021 Equity Incentive Plan under the Nasdaq employment inducement exemption.
- Vesting Schedule: The RSU grant vests 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal quarterly installments over the subsequent three years.
- Strategic Context: The appointment is linked to an Exclusive License Agreement between Tivic Health Systems and Statera Biopharma, Inc., executed on February 11, 2025.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or operational outlook. It includes standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to various risks and uncertainties. The employment is "at-will," and separation benefits are limited to six months of base salary and COBRA coverage only in cases of termination without cause or resignation for good reason after six months of service.
Investor Verification Checklist
- Verify the terms of the Exclusive License Agreement with Statera Biopharma, Inc. filed on February 12, 2025, to understand the strategic rationale for the COO appointment.
- Review the full text of the Executive Employment Agreement (Exhibit 10.1) for detailed definitions of "good reason" and "cause."
- Confirm the impact of the 600,000 RSU grant on the company's total share count and potential dilution, noting it was granted outside the standard equity plan.
- Monitor future filings for the integration of the Tivic Biopharma division under Mr. Handley's leadership.